このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

PuraPharm 過去の業績

過去基準チェック /06

PuraPharmの収益は年間平均-12.4%の割合で減少していますが、 Pharmaceuticals業界の収益は年間増加しています。収益は年間5.9% 11%割合で減少しています。

主要情報

-12.4%

収益成長率

-2.8%

EPS成長率

Pharmaceuticals 業界の成長	5.6%
収益成長率	-11.0%
株主資本利益率	-69.2%
ネット・マージン	-26.1%
前回の決算情報	31 Dec 2023

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

収支内訳

PuraPharm の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SEHK:1498 収益、費用、利益 ( )HKD Millions
日付	収益	収益	G+A経費
31 Dec 23	407	-106	266
30 Sep 23	410	-112	281
30 Jun 23	412	-118	296
31 Mar 23	430	-119	311
31 Dec 22	448	-120	326
30 Sep 22	518	-147	357
30 Jun 22	588	-174	388
31 Mar 22	624	-148	397
31 Dec 21	660	-122	405
30 Sep 21	642	-45	393
30 Jun 21	624	32	380
31 Mar 21	613	32	378
31 Dec 20	602	32	375
30 Sep 20	622	-69	390
30 Jun 20	643	-171	406
31 Mar 20	669	-199	430
31 Dec 19	696	-227	455
30 Sep 19	694	-132	454
30 Jun 19	692	-38	453
31 Mar 19	719	-8	450
31 Dec 18	746	21	447
30 Sep 18	730	13	447
30 Jun 18	715	6	448
31 Mar 18	653	4	423
31 Dec 17	592	2	399
30 Sep 17	589	17	371
30 Jun 17	587	33	343
31 Mar 17	561	33	326
31 Dec 16	536	32	308
30 Sep 16	518	38	290
30 Jun 16	499	44	271
31 Mar 16	487	36	266
31 Dec 15	474	28	260
30 Sep 15	436	24	238
30 Jun 15	398	20	216
31 Mar 15	382	27	198
31 Dec 14	366	34	180
31 Dec 13	342	26	182

質の高い収益: 1498は現在利益が出ていません。

利益率の向上: 1498は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 1498は利益が出ておらず、過去 5 年間で損失は年間12.4%の割合で増加しています。

成長の加速: 1498の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 1498は利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 1.3% ) と比較することは困難です。

株主資本利益率

高いROE: 1498は現在利益が出ていないため、自己資本利益率 ( -69.23% ) はマイナスです。

PuraPharm 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Recent updates

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06